A new research institute launching today is seeking to create a world-leading asset for the NHS by improving the science behind healthcare organisation and delivery.
A new collaboration between the University of Cambridge, Papworth Hospital NHS Foundation Trust and Sunway Medical Centre in Malaysia will see researchers and clinicians from the two countries working together across borders and disciplinary divides to tackle some of the world’s major health challenges.
With the official launch today of the next stage in the Government’s Life Sciences Industrial Strategy, Cambridge can have a key role to deliver jobs, growth and investment for the East of England.
When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.
One of the world’s leading childhood brain tumour experts, Professor Richard Gilbertson, has been appointed as Li Ka Shing Chair of Oncology in Cambridge and Director of the Cambridge Cancer Centre. He will take up his appointment in August.
Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
A partnership led by the Medical Research Council (MRC) has awarded the University of Cambridge £25 million to provide cutting-edge equipment and infrastructure for its clinical research, from imaging single disease cells through to improved targeting of treatments for patients.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.